Introduction
============

Adult-onset Still\'s disease (AOSD) is a rare systemic disease of unknown etiology. The signs are nonspecific, including a fever, arthralgia and rash. The diagnosis of AOSD is sometimes difficult because of the lack of specific diagnostic markers. While Yamaguchi\'s classification criteria ([@B1]) are widely used for the diagnosis, clinicians must exclude infection, malignancy and other rheumatic diseases. The serum ferritin and interleukin (IL)-18 levels are useful for the diagnosis and evaluation of the disease activity of AOSD ([@B2],[@B3]).

Macrophage activation syndrome (MAS) and disseminated intravascular coagulation (DIC) are severe complications that adversely affect the prognosis ([@B4]). In the treatment of AOSD, glucocorticoid and immunosuppressants, such as cyclosporine (CyA) and methotrexate (MTX), are frequently used. The efficacy of IL-6 inhibitor has been reported recently as well ([@B5]).

Although AOSD most commonly affects young persons, a few patients develop it at an advanced age. The mean age of typical AOSD is about 36 years ([@B6]), with peak ages of 15-25 and 36-46 years ([@B7]). However, some cases of elderly-onset Still\'s disease (EOSD) have also been reported ([@B8]-[@B31]). The oldest such case was 88 years old at the disease onset ([@B8]). The frequency of EOSD is so low that the literature is limited to only a few case reports, with no reviews available, so the overall clinical features of EOSD remain unclear.

We herein report a 74-year-old woman who developed AOSD complicated by MAS. She showed typical signs, such as a fever, rash, sore throat and lymphadenopathy. Laboratory tests showed liver dysfunction and elevated serum ferritin and IL-18 levels. She developed MAS during high-dose glucocorticoid therapy, but this improved after starting glucocorticoid pulse therapy with CyA. The cytokine profile was useful for the early diagnosis of MAS. In addition, we conducted a literature review of patients who developed EOSD after 70 years of age and compared them with the findings of overall AOSD cases in order to identify the clinical features specific to EOSD.

Case Report
===========

A 74-year-old woman was admitted to our hospital because of an antimicrobial-resistant fever, rash and sore throat. Nineteen days before admission, itchy erythema had developed on her back, buttocks and femur. Fourteen days previously, a remittent fever over 39℃ and sore throat had developed. She was admitted to another hospital and treated with antibiotics without improvement.

On admission to our hospital for further treatment, her orientation was clear. Her body temperature was 38.6℃, blood pressure 129/59 mmHg and heart rate 85 beats per minute. She had taken azilsartan and atorvastatin regularly for hypertension and dyslipidemia for several years. Her family had no known history of rheumatic diseases. She had an allergy to contrast agents. On a physical examination, she had itchy erythema on her back and left upper arm with Koebner phenomenon, which worsened as the fever increased ([Fig. 1](#g001){ref-type="fig"}). She had no swollen superficial lymph nodes. Her pharynx was normal. She had no arthritis or purpura. Laboratory tests showed leukocytosis with neutrophil predominance and elevation of serum C-reactive protein (CRP), ferritin and IL-18 levels ([Table 1](#t001){ref-type="table"}). Antinuclear antibodies, rheumatoid factors and anti-neutrophil cytoplasmic antibodies were negative. Although an interferon-gamma release assay was positive, both a smear and polymerase chain reaction test of sputum for *Mycobacterium tuberculosis* were negative (three-fold repetition).

![Skin findings. The itchy rash with Koebner phenomenon worsened when the patient had a fever.](1349-7235-59-0721-g001){#g001}

###### 

Laboratory Data on Admission and at Time of MAS Development.

                               On admission      Complicated by MAS      Normal range
  ------------------------- -- -------------- -- -------------------- -- --------------
  Urinalysis                                                             
  Protein                      \-                \-                      
  Occult blood                 \-                \-                      
  Blood count                                                            
  White blood cells (/μL)      11,970            20,240                  3,300-8,800
  Neutrophil (%)               88.2              97.0                    42.0-74.0
  Hb (g/dL)                    9.6               9.3                     13.5-17.0
  Plt (/μL)                    39.0              28.5                    13.0-35.0
  ESR (mm/hr)                  140               56                      
  Serum chemistry                                                        
  BUN (mg/dL)                  13.3              21.9                    8-22
  Cr (mg/dL)                   0.75              0.73                    0.60-1.00
  Na (mEq/L)                   134               132                     135-149
  K (mEq/L)                    4.3               5.1                     3.5-4.9
  Cl (mEq/L)                   98                98                      96-108
  AST (IU/L)                   41                1,989                   13-33
  ALT (IU/L)                   22                821                     8-42
  LDH (IU/L)                   357               2,643                   119-229
  TP (g/dL)                    7.4               6.0                     6.7-8.3
  Alb (g/dL)                   2.5               2.4                     4.0-5.0
  TG (mg/dL)                   78                139                     30-150
  Ferritin (ng/mL)             8,412             34,160                  6.9-323
  FDP-DD (μg/mL)               6.2               33.8                    \<1.0
  Immunological findings                                                 
  CRP (mg/dL)                  15.7              2.9                     0.0-0.3
  IgG (mg/dL)                  1,775             870-1,700               
  IgA (mg/dL)                  283               110-410                 
  IgM (mg/dL)                  89.5              33-190                  
  C3 (mg/dL)                   184.7             65-135                  
  C4 (mg/dL)                   41.7              13-35                   
  Anti-nuclear antibody        ×40               \-                      
  RF (IU/mL)                   2.0               \<20                    
  MPO-ANCA                     \-                \-                      
  PR3-ANCA                     \-                \-                      
  sIL-2R (U/mL)                1,490             2,870                   220-530
  Cytokine                                                               
  IL-18 (pg/mL)                33,500            210,000                 \<500
  IL-6 (pg/mL)                 42                18                      \<5
  neopterin (nmol/L)           21.8              113                     \<5
  sTNF-R I (pg/mL)             4,240             7,000                   484-1,407
  sTNF-R II (pg/mL)            6,900             46,500                  892-2,262
  sTNF-R II/I                  1.6               6.6                     

MAS: macrophage activation syndrome

Plain computed tomography (CT) revealed only swelling of the bilateral axillary lymph nodes, without any other abnormal findings, such as hepatosplenomegaly or signs of tuberculosis infection. Contrast-enhanced CT was not performed because of her allergy to contrast agents. Four sets of blood cultures were negative. Laboratory tests also showed past Epstein-Barr virus and cytomegalovirus (CMV) infections and negative results for hepatitis B virus (HBV) surface antigen, HBV surface antibodies, HBV core antibodies and hepatitis C virus antibodies. Upper endoscopy revealed no abnormalities. A fecal occult blood test was negative. A skin biopsy of the erythema on her back showed infiltration of inflammatory cells, including neutrophils and eosinophils, around the vessels and interstitium of the superficial dermic layer without any signs of malignant lymphoma or other malignancy ([Fig. 2](#g002){ref-type="fig"}). After excluding malignancy and infection, AOSD was diagnosed according to Yamaguchi\'s classification criteria ([@B1]).

![A skin biopsy. Infiltration of inflammatory cells, including neutrophils and eosinophils, around vessels and the interstitium of the superficial dermic layer (Hematoxylin and Eosin staining. A ×40, B ×400).](1349-7235-59-0721-g002){#g002}

On the 6th hospital day, 50 mg/day (1 mg/kg/day) of prednisolone with isoniazid was administered. Her symptoms showed improvement on the following day. The serum CRP and ferritin levels decreased to 0.7 mg/dL and 2,351 ng/mL, respectively. However, on the 19th hospital day, a fever over 38℃ and erythema developed transiently. Laboratory findings showed increased serum CRP, ferritin, liver enzyme, D-dimer and IL-18 levels without cytopenia or increased serum triglyceride levels ([Table 1](#t001){ref-type="table"}). Abdominal ultrasound did not reveal hepatosplenomegaly. The serum cytokine profile showed typical findings of AOSD ([@B32]-[@B34]). MAS was diagnosed clinically.

Before the results of a bone marrow biopsy became available, combined intravenous methylprednisolone pulse therapy (1,000 mg/day for 3 days) with CyA was administered, resulting in the immediate improvement of her signs and normalization of serum CRP level. After that, the bone marrow biopsy findings confirmed the presence of hemophagocytosis without any signs of malignancy ([Fig. 3](#g003){ref-type="fig"}). On the 36th hospital day, CMV reactivation developed and was successfully treated with ganciclovir. She was discharged on the 62nd hospital day ([Fig. 4](#g004){ref-type="fig"}). She has remained in remission with a normal serum ferritin level for two years.

![A bone marrow biopsy. Phagocytosis of granulocytes and RBC by macrophage cells (Hematoxylin and Eosin staining. A ×100, B ×1000).](1349-7235-59-0721-g003){#g003}

![Clinical course. MAS: macrophage activation syndrome, PSL: prednisolone, CyA: cyclosporine, CMV: cytomegalovirus, GCV: ganciclovir, CRP: C-reactive protein](1349-7235-59-0721-g004){#g004}

Literature review
-----------------

We searched Pubmed for publications on EOSD in English that included sufficient clinical information for the purposes of this study, including background factors, laboratory data, treatments and the clinical course. We defined EOSD here as AOSD developing in patients over 70 years old, in view of the lack of any agreed-upon definition of EOSD in the literature. Our search thus identified 24 EOSD cases ([@B8]-[@B31]).

First, we compared the clinical features between the 25 EOSD cases (the present case and the 24 cases from the literature review) and the overall AOSD group ([@B7],[@B35]-[@B45]) ([Table 2](#t002){ref-type="table"}). The mean onset age was 76.6±4.9 and 24-46 years old in the EOSD and AOSD groups, respectively. EOSD showed similar clinical signs and laboratory findings to overall AOSD. Regarding complications, the frequency of MAS was similar. However, DIC occurred more frequently in the EOSD group than in the AOSD group (20.0% vs. 1.8-6.3%). Regarding treatment, we compared the 25 EOSD cases with 166 Japanese AOSD cases ([@B44]) ([Table 3](#t003){ref-type="table"}). Glucocorticoid use was common, and methylprednisolone therapy was used in about one-third of cases. EOSD cases received immunosuppressants and biologics less frequently than did AOSD cases (24.0% vs. 80.7% and 8.0% vs. 19.9%, respectively). MTX was often used in overall AOSD (41.0%). Regarding the clinical outcome, the rates of remission, relapse and death were similar, but the observation period was longer in the overall AOSD group.

###### 

Clinical Features of EOSD and AOSD.

  --------------------------------------------------------------------------------------
                                                  EOSD\              AOSD\
                                                  n=25               \[Ref. 7, 35-45\]
  -------------------------------------------- -- --------------- -- -------------------
  Japanese patients, n (%)                        17/25 (68)         168/940 (18)

  Epidemiology                                                       

  Mean age, years old                             76.6±4.9           24-46

  Female, n (%)                                   18/25 (74)         45-75%

  Clinical features                                                  

  Fever, n (%)                                    25/25 (100)        85-100%

  Arthritis, n (%)                                19/25 (76)         72-100%

  Typical rash, n (%)                             17/25 (68)         58-94%

  Leukocytes ≥10,000/μL, n (%)                    21/25 (84)         72-98%

  Neutrophils ≥80%, n (%)                         16/21 (76)         55-89%

  Sore throat, n (%)                              16/25 (64)         27-92%

  Lymphadenopathy, n (%)                          9/25 (36)          28-74%

  Splenomegaly, n (%)                             7/25 (28)          29-79%

  Elevated liver enzymes, n (%)                   21/25 (84)         21-76%

  Negative for rheumatoid factor, n (%)           21/22 (95)         93-100%

  Negative for antinuclear antibodies, n (%)      21/21 (100)        89-100%

  Complications                                                      

  MAS, n (%)                                      5/25 (20)          12-21%

  DIC, n (%)                                      5/25 (20)          1.8-6.3%

  Infection, n (%)                                PCP 2/25 (8)\      NA
                                                  CMV 4/25 (16)      

  ARDS, n (%)                                     1/25 (4)           NA

  Interstitial pneumonia, n (%)                   1/25 (4)           NA

  Multi-organ dysfunction, n (%)                  1/25 (4)           NA

  Cerebellar hemorrhage, n (%)                    1/25 (4)           NA

  Subacute hepatitis, n (%)                       1/25 (4)           NA

  Malignancy, n (%)                               1/25 (4)           NA

  Inflammatory myopathy, n (%)                    1/25 (4)           NA
  --------------------------------------------------------------------------------------

EOSD: elderly-onset Still's disease, AOSD: adult-onset Still's disease, MAS: macrophage activation syndrome, DIC: disseminated intravascular coagulation, ARDS: acute respiratory distress syndrome, PCP: pneumocystis pneumonia, CMV: cytomegalovirus, NA: not available

###### 

Medication and Clinical Outcome of EOSD and AOSD.

  -------------------------------------------------------------------------
                                           EOSD\        AOSD\
                                           n=25         n=166 \[Ref. 44\]
  ------------------------------------- -- --------- -- -------------------
  Japanese patients, n (%)                 17 (68)      166 (100)

  Medication                                            

  Glucocorticoid, n (%)                    23 (92)      160 (96.4)

  Pulse glucocorticoid therapy, n (%)      7 (28)       52 (31.3)

  NSAIDs, n (%)                            9 (36)       73 (44.0)

  Immunosuppressants, n (%)                6 (24)       134 (80.7)

  Biologics, n (%)                         2 (8)        33 (19.9)

  IVIG, n (%)                              2 (8)        \-

  Others, n (%)                            \-           8 (4.8)

  Clinical outcome                                      

  Remission, n (%)                         23 (92)      145/164 (88.4)

  Flare, n (%)                             11 (44)      66/169 (39.1)

  AOSD-related death, n (%)                0 (0)        0 (0)

  Follow up time, months                   23.7         58.8
  -------------------------------------------------------------------------

EOSD: elderly-onset Still's disease, AOSD: adult-onset Still's disease, NSAIDs: non-steroidal anti-inflammatory drugs, IVIG: intravenous immunoglobulin

Next, we identified 5 EOSD cases complicated by MAS, including the present case ([@B8],[@B15],[@B28],[@B29]), and compared the findings with AOSD cases complicated by MAS from the literature review ([@B46]) ([Table 4](#t004){ref-type="table"}). The mean onset age of MAS was 76.8±7.3 and 40.2±16.0 years old in the EOSD and AOSD groups, respectively. With respect to treatment, glucocorticoids and CyA were the most commonly used agents. EOSD patients received intravenous immunoglobulin (IVIG) and MTX less frequently than did AOSD patients. Although EOSD may show less mortality due to MAS than AOSD, a bias due to the small sample size could not be excluded.

###### 

Comparison between EOSD and AOSD Cases Complicated with MAS.

  --------------------------------------------------------------------
                                EOSD with MAS\      AOSD with MAS\
                                n=5                 n=48 \[Ref. 46\]
  -------------------------- -- ---------------- -- ------------------
  Epidemiology                                      

  Mean age, years old           76.9±8.4            40.2±16.0

  Females, n (%)                5 (100)             35 (72.9)

  Treatment for MAS                                 

  Glucocorticoids, n (%)        4 (80)              43 (90)

  Cyclosporine, n (%)           2 (40)              14 (29)

  Anti- IL-6, n (%)             1 (20)              \-

  IVIG, n (%)                   \-                  19 (40)

  Methotrexate, n (%)           \-                  11 (23)

  Cyclosphosphamide, n (%)      \-                  6 (13)

  Anakinra, n (%)               \-                  1 (2)

  Anti-TNF, n (%)               \-                  1 (2)

  Immediate outcome                                 

  Alive, n (%)                  5 (100)             42 (88)

  Deceased, n (%)               \-                  6 (12)

  Follow up time, months        14.2±6.5            17.5±32.3
  --------------------------------------------------------------------

EOSD: elderly-onset Still's disease, AOSD: adult-onset Still's disease, MAS: macrophage activation syndrome, IL-6: interleukin-6, IVIG: intravenous immunoglobulin, TNF: tumor necrosis factor

In this literature review, the overall AOSD group included some EOSD cases because reports of AOSD included all ages. However, as the rate of EOSD cases in the overall AOSD group was considered to be less than 10-20% ([@B4]), we did not consider this to have substantially influenced the total trend mentioned above. Furthermore, we did not perform a statistical analysis because of the different cohorts used here and the small sample sizes.

Discussion
==========

We described a 74-year-old woman who developed AOSD complicated by MAS. Although EOSD is rare, elderly patients can develop AOSD, and the number of such cases is expected to increase because of the aging of society. The literature review showed that cases of EOSD had almost the same clinical signs, including MAS, as overall AOSD, although they showed a tendency to develop DIC more frequently than the overall AOSD group. Immunosuppressants were noted to be less frequently used in EOSD patients than in AOSD patients. As elderly patients can develop typical AOSD, clinicians should not exclude AOSD from the differential diagnosis in this group.

The age at the onset of AOSD has been increasing. An investigation from Japan reported that the average age at the onset of AOSD was 38.1±14.3 years old in 1994 ([@B47]), in contrast to 46±19 years old in 2010 ([@B44]). Another report in 2016 from Japan stated that the mean onset age was 53.1±19.6 years old ([@B4]). About 23% of cases developed it at ≥65 years old and about 16% at ≥75 years old ([@B4]). This has been attributed to the marked aging of the population now occurring in Japan ([@B4]). For this reason, it can be surmised that, as the population continues to age, the age at the onset of AOSD will also continue to increase.

The literature review showed EOSD to be associated with almost the same clinical signs, including MAS, as typical AOSD, although DIC appeared to be more frequent in EOSD patients than in AOSD patients. With respect to complications, while the total prevalence of MAS and DIC has been reported not to differ appreciably across patient age groups ([@B4]), we found that DIC was more frequent in EOSD than in AOSD, despite a similar frequency of MAS. MAS is a severe complication related to mortality ([@B48],[@B49]), and an older age was shown to be associated with increased mortality in AOSD ([@B50]). We could not determine the prognosis statistically because a different cohort was used. In addition, we were unable to determine the prevalence of malignant diseases, infection or other co-morbidities throughout the total clinical course in typical AOSD cases because of a lack of such data in the literature; therefore, whether or not these conditions are more prevalent in EOSD than in AOSD remains unclear.

EOSD is associated with various complications, including opportunistic infections, such as CMV infection ([@B15],[@B17],[@B29]) and pneumocystis pneumonia ([@B11],[@B29]), acute respiratory distress syndrome ([@B30]), interstitial pneumonia (IP) ([@B23]), multi-organ dysfunction ([@B23]), subacute hepatitis ([@B24]), cerebellar hemorrhaging ([@B22]), malignancy ([@B16]) and inflammatory myopathy with abundant macrophages ([@B28]). Two patients with EOSD died of either IP and multi-organ failure ([@B23]) or malignancy ([@B16]). In AOSD, the mortality was reported to increase with age ([@B4]). In addition, as the prevalence of malignancy is increased in older persons, and given that a case of paraneoplastic syndrome with clinical features similar to those of AOSD was reported ([@B51]), clinicians should consider the possibility of malignancy when diagnosing EOSD. Cases of AOSD associated with malignancy tend to be older at the onset of symptoms than typical AOSD cases ([@B52]). Therefore, although the clinical features of EOSD are similar to those of typical AOSD, it is important to exclude malignant disease and be alert for the possible development of complications, such as MAS and DIC, during the clinical course of EOSD.

Although glucocorticoid was commonly used in both EOSD and AOSD, immunosuppressants such as MTX and CyA were used less often in cases of EOSD. This is similar to the situation with systemic lupus erythematosus, in which immunosuppressants are also less frequently used in elderly patients than in younger ones ([@B53],[@B54]). Considering the rates of remission and relapse in EOSD, the response to glucocorticoids might be better in EOSD than in AOSD. In contrast, immunosuppressants and biologics may tend to be avoided in EOSD patients due to concerns about infection. A patient with EOSD who discontinued IL-6 inhibitor due to severe infection has been reported ([@B19]). Immunosuppressants and biologics need to be prescribed particularly carefully in EOSD cases.

Several limitations associated with the present study warrant mention. First, the race-related difference between the EOSD and overall AOSD groups may have influenced the clinical features of each group. Japanese patients, who have lower frequencies of chronic pattern ([@B6],[@B44],[@B55]) and MTX use ([@B4],[@B35],[@B36]), comprised 68% and 18% of the EOSD and overall AOSD groups, respectively. Second, the EOSD group comprised rare case reports, suggesting possible selection bias. Special attention should be paid to these points when comparing these two groups.

In conclusion, AOSD can develop even in persons over 70 years old with typical clinical features, including severe complications, such as MAS. EOSD may be complicated by DIC more frequently than AOSD. The diagnosis of EOSD can sometimes be delayed because clinicians are less likely to consider it in elderly patients ([@B56]). Including EOSD properly as a differential diagnosis can help prevent expensive and/or excessive examinations ([@B20],[@B31]). This report draws attention to EOSD to make clinicians aware that elderly patients can develop typical AOSD and that such cases can be expected to increase in number with the general aging of society.
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